ITGAE and inflammatory bowel disease: In contrast to the decreased numbers of the CD103+ myeloid tolerogenic DCs in MLNs, tolerogenic plasmacytoid DCs (pDCs) have been shown to be increased in MLNs of patients with IBD, but these pDCs do not seem to alter disease progression [28,29].